



New editorial team on *leukemia and lymphoma*

Aaron Polliack Editor-in-Chief

To cite this article: Aaron Polliack Editor-in-Chief (2006) New editorial team on *leukemia and lymphoma*, Leukemia & Lymphoma, 47:1, i-i, DOI: [10.1080/10428190500465234](https://doi.org/10.1080/10428190500465234)

To link to this article: <https://doi.org/10.1080/10428190500465234>



Published online: 01 Jul 2009.



Submit your article to this journal [↗](#)



Article views: 627



View related articles [↗](#)

EDITORIAL

New Editorial Team on *Leukemia and Lymphoma*

We are writing to inform you about changes that will take place at *Leukemia & Lymphoma* as from January 2006, which include the addition of two new chief editors and changes in the content formats. The two editors who will join Professor Aaron Polliack as joint chief editors are Dr Koen van Besien (University of Chicago Medical Center, USA) and Dr John Seymour (Peter MacCallum Cancer Center, Melbourne, Australia). Both have already contributed much to the journal in their capacities as main editors during the past few years and both are well aware of the challenges ahead for the journal in the future. This is not a new involvement in journal affairs for them at all, but as joint Editors-in-Chief this represents a further commitment to the journal. Both are already well established and internationally recognized clinicians who will, without a doubt, work energetically and contribute much to the journal in their own style. The three of us know each other well and are delighted to be working together as a team to advance the journal in the future. During the course of 2006 new members will be added to the editorial board in a rotatory fashion.

Regular readers of *Leukemia & Lymphoma* will also notice some further changes this year in the content and structure of the Journal. We will feature more invited Editorials, which will provide interesting insights into, and a succinct overview, of current controversies in relevant fields. We are also instigating a new series of Commentaries, where we highlight significant articles published in the Journal with a cogent synopsis and analysis which will shed additional light on the topic and place the published article in the broader perspective of the existing literature in the field.

The other major change authors will have already been informed of, and readers are shortly to notice, is that the journal will no longer publish Case Reports in their current format. In recent years, approximately a quarter of the journal's content has comprised Case Reports, with a detrimental effect on the journal's Impact Factor. However, we are conscious of the value our readers and authors attach to these informative articles, and therefore rather than simply stopping their publication, we will reformat these into Letters to the Editors. Please note that we shall only publish case reports that will impact and enhance clinical or laboratory practice. We will also continue to publish Correspondence articles related to comments on previously published papers in the journal, or those that highlight current topical or controversial issues being debated in the community.

The revised Instructions to Author can be found at the back of this issue and on our website (<http://www.tandf.co.uk/journals/titles/10428194.asp>). We would encourage authors to familiarize themselves with these before submitting an article to the journal.

Leukemia & Lymphoma continues to be an essential resource for the community we serve and this is borne out by increased submissions to the journal and over a quarter of a million hits on the website last year. We continue to look to your ongoing support in helping us to develop the Journal over the next year, and trust you will enjoy some of the new features the journal has to offer.

Aaron Polliack
Editor-in-Chief